Novo Nordisk has been experiencing some market turbulence, but there are indicators that this is not a long-term downward trend. Despite significant recent losses, professional asset managers are continuing to expand their holdings in the company. This includes
Manchester Capital Management and
Vontobel Holding Ltd., among others who have been purchasing the company's shares. There's also an expectation of major catalysts on the horizon. Even renowned investor
Jim Cramer anticipates promising financial prospects for Novo Nordisk by 2025. It's worth noting that
Bernstein has raised the company's stock target and
Morgan Stanley has recently initiated coverage at equal weight. However, there have been concerns regarding disappointing trial results for
CagriSema,
Novo Nordisk's obesity drug. While Q4 results for
Wegovy, another obesity drug from
Novo Nordisk, displayed doubled sales, the company's shares plummeted on the release of the CagriSema trial data. Analysts predict a volatile short-term trend for Novo Nordisk but have a positive long-term perspective on its growth potential in the international dividends market.
Novo Nordisk Stocks News Analytics from Fri, 22 Nov 2024 08:00:00 GMT to Sat, 15 Feb 2025 23:54:05 GMT -
Rating 0
- Innovation 5
- Information 6
- Rumor 1
